nach oben

Erschienen in:

01.03.2015 | Original Article

Lung involvement in children with lysinuric protein intolerance

verfasst von: Sarah Valimahamed-Mitha, Laureline Berteloot, Héloise Ducoin, Chris Ottolenghi, Pascale de Lonlay, Jacques de Blic

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Lysinuric protein intolerance (LPI) is a rare multisystemic metabolic disease. The objective of the study was to describe presentation and course of lung involvement in a cohort of ten children.

Patients and methods

Retrospective review of patients followed at Necker-Enfants Malades University Hospital between 1980 and 2012 for a LPI. In patients with lung involvement, clinical data, chest radiographs, pulmonary function tests, bronchoalveolar lavages, and lung biopsies were analyzed. The first and last high-resolution computed tomography (HRCT) were also reviewed.

Results

Lung involvement was observed in ten of 14 patients (71 %). Five patients had an acute onset of respiratory symptoms, three had a progressive onset and two were free of symptoms. During the period studied, six patients (60 %) died, all in a context of respiratory failure. Clinical presentation and course were highly variable, even in the same family. HRCT were performed in seven cases, showing in all cases an interstitial pattern and fibrosis in four. All ten patients had pulmonary alveolar proteinosis (PAP) confirmed by histopathological analysis. Five patients had pulmonary fibrosis (at biopsy and/or HRCT scan). Two patients underwent whole lung lavages, without efficiency.

Conclusion

PAP is a constant feature in children with LPI and lung involvement. Pulmonary fibrosis is frequent and these two pathologies may develop independently. This study shows the heterogeneity of presentation and outcome. Lung injury could be secondary to impaired phagocytic function and abnormal inflammatory and immune responses intrinsic to the SLC7A7 mutant phenotype. HRCT is recommended to detect lung involvement.

Barilli A, Rotoli BM, Visigalli R et al (2010) In lysinuric protein intolerance system y + L activity is defective in monocytes and in GM-CSF-differentiated macrophages. Orphanet J Rare Dis 5:32CrossRefPubMedCentralPubMed

Barilli A, Rotoli BM, Visigalli R et al (2012) Impaired phagocytosis in macrophages from patients affected by lysinuric protein intolerance. Mol Genet Metab 105(4):585–589CrossRefPubMed

Borsani G, Bassi MT, Sperandeo MP et al (1999) SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet 21(3):297–301CrossRefPubMed

Carey B, Trapnell BC (2010) The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 135(2):223–235CrossRefPubMedCentralPubMed

Ceruti M, Rodi G, Stella GM et al (2007) Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis 2:14CrossRefPubMedCentralPubMed

de Blic J (2004) Pulmonary alveolar proteinosis in children. Paediatr Respir Rev 5(4):316–322CrossRefPubMed

de Blic J, Midulla F, Barbato A et al (2000) Bronchoalveolar lavage in children. ERS task force on bronchoalveolar lavage in children. European respiratory society. Eur Respir J 15(1):217–231CrossRefPubMed

DiRocco M, Garibotto G, Rossi GA et al (1993) Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr 152(5):437–440CrossRefPubMed

Douda DN, Farmakovski N, Dell S et al (2009) SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance. Orphanet J Rare Dis 4:29CrossRefPubMedCentralPubMed

Gordon WC, Gibson B, Leach MT et al (2007) Haemophagocytosis by myeloid precursors in lysinuric protein intolerance. Br J Haematol 138(1):1CrossRefPubMed

Granillo OM, Brahmajothi MV, Li S et al (2008) Pulmonary alveolar epithelial uptake of S-nitrosothiols is regulated by L-type amino acid transporter. Am J Physiol Lung Cell Mol Physiol 295(1):L38–43CrossRefPubMedCentralPubMed

Guzel-Ozanturk A, Ozgul RK, Unal O et al (2013) Molecular and clinical evaluation of Turkish patients with lysinuric protein intolerance. Gene 521(2):293–295CrossRefPubMed

Hansell DM, Bankier AA, MacMahon H et al (2008) Fleischner society: glossary of terms for thoracic imaging. Radiology 246(3):697–722CrossRefPubMed

Kerem E, Elpelg ON, Shalev RS et al (1993) Lysinuric protein intolerance with chronic interstitial lung disease and pulmonary cholesterol granulomas at onset. J Pediatr 123(2):275–278CrossRefPubMed

Kitamura T, Tanaka N, Watanabe J et al (1999) Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190(6):875–880CrossRefPubMedCentralPubMed

Koizumi A, Shoji Y, Nozaki J et al (2000) A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group. Hum Mutat 16(3):270–271CrossRefPubMed

Ogier De Baulny H, Schiff M, Dionisi-Vici C (2012) Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. Mol Genet Metab 106(1):12–17CrossRefPubMed

Palacin M, Borsani G, Sebastio G (2001) The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev 11(3):328–335CrossRefPubMed

Palacin M, Bertran J, Chillaron J et al (2004) Lysinuric protein intolerance: mechanisms of pathophysiology. Mol Genet Metab 81(Suppl 1):S27–37CrossRefPubMed

Parenti G, Sebastio G, Strisciuglio P et al (1995) Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr 126(2):246–251CrossRefPubMed

Parto K, Penttinen R, Paronen I et al (1993a) Osteoporosis in lysinuric protein intolerance. J Inherit Metab Dis 16(2):441–450CrossRefPubMed

Parto K, Svedstrom E, Majurin ML et al (1993b) Pulmonary manifestations in lysinuric protein intolerance. Chest 104(4):1176–1182CrossRefPubMed

Santamaria F, Parenti G, Guidi G et al (1996) Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med 153(2):731–735CrossRefPubMed

Santamaria F, Brancaccio G, Parenti G et al (2004) Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 145(2):268–272CrossRefPubMed

Sebastio G, Sperandeo MP, Andria G (2011) Lysinuric protein intolerance: reviewing concepts on a multisystem disease. Am J Med Genet C: Semin Med Genet 157(1):54–62CrossRef

Simell O (2001) Lysinuric protein intolerance and other cationic aminoacidurias. In: Valle D et al (eds) Scriver CR BD. The metabolic and molecular bases of inherited disease. New York, McGraw-Hill, pp 4933–4955

Tanner LM, Nanto-Salonen K, Niinikoski H et al (2007) Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance. J Pediatr 150(6):631–634CrossRefPubMed

Torrents D, Mykkanen J, Pineda M et al (1999) Identification of SLC7A7, encoding y + LAT-1, as the lysinuric protein intolerance gene. Nat Genet 21(3):293–296CrossRefPubMed

Trapnell BC, Whitsett JA, Nakata K (2003) Pulmonary alveolar proteinosis. N Engl J Med 349(26):2527–2539CrossRefPubMed

Titel: Lung involvement in children with lysinuric protein intolerance
verfasst von: Sarah Valimahamed-Mitha
Laureline Berteloot
Héloise Ducoin
Chris Ottolenghi
Pascale de Lonlay
Jacques de Blic
Publikationsdatum: 01.03.2015
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 2/2015
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-014-9777-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background and objectives

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Mutations in hereditary phosphoglucomutase 1 deficiency map to key regions of enzyme structure and function

Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria

Screening for cerebrotendinous xanthomatosis

Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease

Chaperone therapy for homocystinuria: the rescue of CBS mutations by heme arginate